Journal: Science Advances
Article Title: Discovery and preclinical evaluation of monoclonal antibodies and bispecific engagers targeting the NKG2A inhibitory receptor
doi: 10.1126/sciadv.adu0690
Figure Lengend Snippet: ( A ) The IFN-⍺ + , TNFα + , and GrzB + population (%) of IL-2–activated NK cells after antibodies treatment with different NKG2A binding valency (monovalent, bivalent, tetravalent, or multivalent) in the coculture system with A549 cells, E:T ratio of 5:1, for 24 hours. ( B ) Internalization of NKG2A antibodies in NK cells, assessed by labeling the antibody with a pH-sensitive dye to monitor endocytosis. Durvalumab and pertuzumab (ptz IgG1) were included as controls. (A and B) Each symbol represents the value obtained from individual healthy donors. Significance was determined by one-way ANOVA with the Tukey’s post hoc test, * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.
Article Snippet: Primary NK cells were cultured with magnetic-activated cell sorting (MACS) basal NK media with supplementary (Miltenyi Biotec, 130-114-429), 10% (v/v) human serum (Sigma-Aldrich), and human IL-2 (hIL-2) (50 IU/ml; Miltenyi Biotec).
Techniques: Binding Assay, Labeling